Skip to main content

Application Number : 9325/DELNP/2007

During examination the patent office objected that application was within the scope of Section 4 of the Indian Patent Act and Sub-section 1 of Section 20 of the Atomic Energy Act, 1962 as the subject matter of instant application relates to A catalyst deposited on the carrier in addition to silver, one or more further elements selected from the group of nitrogen, sulfur, phosphorus, boron, fluorine, Group IA metals, Group IIA metals, rhenium, molybdenum, tungsten, chrontium, titanium, hafnium, zirconium, vanadium, manganese, thallium, thorium, tantalum, niobium, gallium and geimaiuum and mixtures thereof. The weight per cent mention in Atomic Energy Notification category 0A303. So it was proposed to send the matter to Atomic Energy for clearance.

Objection under Section 4 was raised, which  Anand and Anand successfully overcame based on written submissions and representations made before the Department of Atomic energy (DAE). Granted without a hearing.

Significance: Atomic Energy-related Inventions not allowed in India or are significantly delayed. Anand and Anand was able to get a patent grant with their submissions.

Team Anand and Anand: Priyanka Dubey

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
•
Nov 02, 2026

First published by AsiaIP. Author: Lakshmidevi Somanath Copyright law has traditionally addressed the asymmetry between the costs of creating a work and

What is Copyright Worth When Machines Do the Creating? Lessons from Streaming and Gaming
News & Updates, Thought Leadership
•
Oct 31, 2026

A startup has developed a new technology, filed a patent application and begun building its product. The filing is an important milestone. But what happens

Your Startup Has Filed a Patent. Now What? The Commercial Value of IP
News & Updates, Thought Leadership
•
Oct 29, 2026

‘First published on Chambers’ By: Lakshmidevi Somanath and Kanishka Vaish Leveraging the Process of Interim Injunction as a Strategic Instrument in

Leveraging the Process of Interim Injunction as a Strategic Instrument in India & U.S. IP Litigation
News & Updates, Thought Leadership
•
Oct 27, 2026

When a pharmaceutical company develops a new formulation of an existing drug, is it creating a genuine innovation or extending its monopoly over a medicine

Evergreening or Genuine Innovation? The Patentability of New Drug Formulations in India